Appointment expected to support initiatives to improve population health management and the company’s planned upgrade from OTCBQB to NASDAQ
Vinay Mehindru Joins Retinalgenix Board of Directors
PETALUMA, Calif., July 26, 2022 (GLOBE NEWSWIRE) — RetinalGenix™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGenix” or the “Company”), today announced the appointment of Vinay Mehindru, MD, MBA to the RetinalGenix Technologies, Inc. Board of Directors.
dr. Mehindru is a multi-talented top executive with over 25 years of healthcare experience. His leadership includes population health and financial performance management. He has led multiple physician performance improvement strategies and built stakeholder alliances with clinical and financial integration. He currently serves on the board of directors of Sanovas, Inc., SteriView™ Technologies, Inc., Intubation Science™, Inc, SinuGeniX™, Inc., OtoGeniX™ Inc., PulmoGeniX™ Technologies, Inc. and GastroGeniX™, Inc.
dr. Mehindru graduated from medical school at the age of 21 and was one of the youngest graduates in his native India. At age 27, he was on the faculty of the Cleveland Clinic, where he was a top internist and researcher in gastroenterology. Vinay has a second residency at the University of Florida in emergency medicine.
Vinay joined a private group of emergency medicine physicians on the east coast of Florida with 47 health care providers, 75 employees, and more than 100,000 annual visits. He has vast experience in airway management; Worked in a level 2 trauma center for 10 years. For 16 years he was an instructor teaching difficult airway management for both cardiovascular life support and pediatric advanced life support.
From the University of Texas at Dallas, he received an Executive MBA with honors, earning him the Beta Gamma Sigma Award presented only to the world’s top 5% of business students. dr. Mehindru is the founder and CEO of Exemplary Health, a fully integrated health plan for self-funded employers, based on the principles of population health management. At AdventHealth, he served as Chief Medical Officer and chaired AdventHealth’s Physician Network, Tampa Bay, a public health company. As president of AdventHealth’s clinically integrated networks, Dr. Mehindru built a network of 1,000 doctors and established quality benchmarks and statistics. He successfully reduced the annual historic increase in the cost of their employee health plan. As a voting member of the AdventHealth West Florida Division Strategy and Growth Council, Dr. Mehindru oversees strategic initiatives of this $1.5 billion revenue division.
dr. Mehindru said: “I am delighted to be on the board of RetinalGenix. This technology is designed to screen large populations at a relatively lower cost and to reduce the overall burden of disease in the given population. It addresses all 3 components of the Institute for Healthcare Improvement (IHI)’s triple goal of population health management: 1. Improve population health 2. Reduce costs per capita 3. Improve experience by improving access .”
“We welcome Dr. Mehindru as a member of the Board of Directors of RetinalGenix Technologies, Inc. His MBA, public health and medical background should complement numerous RetinalGenix initiatives, including the company’s initiatives to improve population health management and the planned upgrade of OTCQB to listing on NASDAQ,” said Jerry. Katzman, MD, president and CEO of RetinalGenix.
Safe Harbor Statement
This press release contains certain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of the words “might,” “believe,” “anticipate,” “intend,” estimate,” “expect,” “may,” “continue,” “forecast,” “potential,” “project,” and similar expressions intended to identify forward-looking statements and statements regarding Dr. Mehindru’s appointment support the the company’s initiatives to improve population health management and the planned upgrade of the list from OTCBQB to NASDAQ and the company’s technology to screen large populations at a relatively lower cost and reduce the overall burden of disease in the given population. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release message and are subject to a number of risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include the contribution of Dr. Mehindru to the company, the ability of the company’s technology to screen large populations at a relatively lower cost and the overall disease burden in the given population and the risk factors described in the company’s annual report on Form 10-K for the year ended December 31, 2021 and the Company’s subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and we make no obligation to update any forward-looking statements in this release as a result of new information, future events or otherwise, except as required by law.
Retinal Genix Technologies, Inc.
Jerry Katzman, CEO
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4641abf8-34d8-4897-8314-321686e36dee